TScan Therapeutics
TCRX
54 hedge funds and large institutions have $187M invested in TScan Therapeutics in 2023 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 13 increasing their positions, 4 reducing their positions, and 0 closing their positions.
225% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 4
156% more capital invested
Capital invested by funds: $73.2M → $187M (+$114M)
69% more funds holding
Funds holding: 32 → 54 (+22)
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
8.16% more ownership
Funds ownership: 65.66% → 73.82% (+8.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$961K |
| 2 |
Aberdeen Group
Edinburgh,
United Kingdom
|
+$916K |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$506K |
| 4 |
Millennium Management
New York
|
+$454K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$398K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$458K |
| 2 |
LBA
Letko, Brosseau & Associates
Montreal,
Quebec, Canada
|
-$53.6K |
| 3 |
BlackRock
New York
|
-$39.9K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$1.67K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
UBS Group
Zurich,
Switzerland
| $8.3K | +$1.41K | +309 | +28% |
|
|
ACA
52
Atlas Capital Advisors
Jackson,
Wyoming
| $5.22K | – | – | – |
|
53
Wells Fargo
San Francisco,
California
| $1.75K | +$69 | +15 | +5% |
|
|
TRCT
54
Tower Research Capital (TRC)
New York
| $251 | +$197 | +43 | New |
|
TCRX Hedge Fund Activity: Q4 2023 in Review
54 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in TScan Therapeutics (TCRX) for Q4 2023, worth a combined $187M — up 156% from $73.2M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new TCRX positions and 0 closed out — a net gain of 22 holders — while 13 added to existing stakes and 4 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $961K. The largest seller was Adage Capital Partners, cutting an estimated $458K.
- 54 institutional investors held TScan Therapeutics (TCRX) as of Q4 2023, up from 32 in Q3 2023.
- Funds reported $187M of TScan Therapeutics stock for Q4 2023, up 156% quarter-over-quarter.
- 22 funds opened new TScan Therapeutics positions in Q4 2023 and 0 closed out, a net change of +22 holders.
- The largest TScan Therapeutics buyer in Q4 2023 was Morgan Stanley, an estimated $961K added.
- The largest TScan Therapeutics seller in Q4 2023 was Adage Capital Partners, an estimated $458K sold.
Based on aggregated 13F filings for Q4 2023.